| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | -7.16 M USD | -5.27 M USD | -3.65 M USD | -5.31 M USD | -2.40 M USD |
| Depreciation & Amortization | 227406 USD | 193139 USD | 162670 USD | 193621 USD | 186388 USD |
| Stock-Based Compensation | 105368 USD | 287455 USD | 456001 USD | 1.19 M USD | 177489 USD |
| Capital Expenditures | 21528 USD | 5115 USD | 0 USD | — | — |
| Cash Flow from Investing | -203902 USD | -321937 USD | -119522 USD | -207870 USD | -102005 USD |
| Cash Flow from Financing | 18.95 M USD | 5.03 M USD | 3.31 M USD | 6.55 M USD | 2.94 M USD |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Free Cash Flow | -7.19 M USD | -5.28 M USD | -3.65 M USD | — | — |
Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain. The company combines magnetic resonance spectroscopy (MRS) imaging with proprietary augmented-intelligence algorithms to create software-as-a-service (SaaS) solutions that help physicians personalize treatment plans and optimize clinical outcomes. The company's primary offering is the NOCISCAN Suite, which uses MRS capabilities to noninvasively analyze the chemical composition of intervertebral discs in the spine. Aclarion's suite includes the NOCISCAN MRS Exam Protocol for standard lumbar MRI exams, the NOCISCAN Post-Processor Suite with NOCICALC and NOCIGRAM applications that process spectroscopy data and calculate degenerative pain biomarkers, and complementary imaging data transfer platforms. By leveraging artificial intelligence to assist in quality control processes and proprietary biomarkers, Aclarion aims to address unmet clinical needs in musculoskeletal pain management and help patients achieve improved health outcomes and pain relief.